Cingulate Inc. (CING)
Cingulate Inc. (CING) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.8M |
| Beta | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.04 |
| P/B (ttm) | 15.06 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | Strong Buy |
| Price Target | 20 (NaN%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
Financial Performance
In 2025, Cingulate's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -22.45M, an increase of 35.57%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for CING stock is "Strong Buy". The 12-month stock price forecast is 20, which is downside of NaN% from the latest price.
Stock Forecasts
